A Phase I Study of Rapamycin in Combination With Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
18 Years
N/A
Both
Liver Cancer
Trial Information
A Phase I Study of Rapamycin in Combination With Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of sirolimus used in combination with bevacizumab
in patients with unresectable hepatocellular carcinoma.
- Determine the toxicity profile of this regimen in these patients.
Secondary
- Determine the clinical activity of this regimen in these patients.
- Determine the pharmacokinetics of sirolimus in these patients.
- Determine the biologically active dose range of sirolimus in these patients.
- Correlate phosphorylated p70S6K activity with clinical response in patients treated
with this regimen.
- Correlate PTEN, 4EBP-1, phosphorylated p70S6K, CD31, and vascular endothelial growth
factor expression with clinical response in patients treated with this regimen.
- Correlate the degree of angiogenesis (as measured by DCE-CT scan) with drug levels and
clinical response.
OUTLINE: This is a dose-escalation study of sirolimus.
Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks and oral sirolimus
once daily. Treatment continues for up to 6 months in the absence of disease progression or
unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of sirolimus until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
of 6 patients experience dose-limiting toxicity. Six additional patients receive treatment
at the MTD.
Blood samples are collected from healthy participants to measure p70S6 kinase activity.
Patients undergo blood sample collection at baseline and periodically during study for
pharmacokinetic and p70S6K activity assessment. Samples are also analyzed by
high-performance liquid chromatography and tandem mass spectrophotometry to determine peak
drug concentrations. Patients without archived tumor samples undergo tumor tissue biopsy at
baseline. Samples are analyzed for PTEN, 4E-BP1, vascular endothelial growth factor,
epidermal growth factor, p70S6K, and CD31 by immunohistochemistry. Patients also undergo
DCE-CT scan at baseline and on day 29 to assess angiogenesis.
After completion of study treatment, patients are followed for 52 weeks.
PROJECTED ACCRUAL: A total of 36 patients and 5 healthy participants will be accrued for
this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Meets 1 of the following criteria:
- Histologically confirmed unresectable hepatocellular carcinoma, meeting all of
the following criteria:
- Failed 0-2 lines of chemotherapy
- Child-Pugh class A or B for liver cirrhosis
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20
mm with conventional techniques or ≥ 10 mm with spiral CT scan
- No known brain metastases
- Bone metastases allowed provided other measurable disease is present
- Healthy participant
PATIENT CHARACTERISTICS:
- ECOG performance status (PS) 0-2 or Karnofsky PS 70-100%
- Life expectancy > 3 months
- WBC ≥ 3,000/mm³
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 3 times upper limit of normal (ULN)
- AST and ALT ≤ 5 times ULN
- Creatinine normal
- PTT < 1.5 times ULN
- Fasting serum cholesterol ≤ 350 mg/dL
- Triglycerides ≤ 300 mg/dL
- Proteinuria < 2+ by urine dipstick OR urine protein ≤ 1 g by 24-hour urine collection
- No history of allergic reactions to compounds of similar chemical or biologic
composition to sirolimus or bevacizumab
- No prior thromboembolic disease that may result in bleeding or clotting problems
related to use of bevacizumab including, but not limited to, the following:
- Esophageal varices
- Bleeding disorders
- Deep vein thromboses
- No history of hematemesis or hemoptysis
- No other uncontrolled illness including, but not limited to, the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness or social situations that would preclude study participation
- No HIV positivity
- Able to take oral medications
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception prior to and during the course of
study treatment
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 28 days since prior surgery and recovered
- No other concurrent investigational agents
- No other concurrent anticancer therapy
- No concurrent traditional Chinese medicine(s)
- No concurrent long term anticoagulation with heparin or warfarin
- Concurrent prophylactic low-dose acetylsalicylic acid for patients at risk of an
arterial thromboembolic event allowed
- Hepatitis B carriers must be on lamivudine during and for 6 months after completion
of study treatment
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Dose-limiting toxicity
Outcome Time Frame:
3 years
Safety Issue:
Yes
Principal Investigator
Choo Su Pin, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
National Cancer Centre, Singapore
Authority:
Singapore: Health Sciences Authority
Study ID:
CDR0000540163
NCT ID:
NCT00467194
Start Date:
December 2006
Completion Date:
Related Keywords:
- Liver Cancer
- adult primary hepatocellular carcinoma
- localized unresectable adult primary liver cancer
- recurrent adult primary liver cancer
- advanced adult primary liver cancer
- Liver Neoplasms
- Carcinoma, Hepatocellular
Name | Location |
|---|
